FMP013疟疾疫苗联合ALFQ佐剂在恒河猴中的安全性、毒性与免疫原性
本研究在恒河猴中评估临床级CSP疫苗FMP013联合ALFQ佐剂的安全性、毒性与免疫原性,采用0-1-2月三剂方案。结果显示仅轻度局部反应,无血液、肝肾功能异常,出现短暂全身炎症反应并于第7天恢复;1 mL ALFQ+20 µg FMP013剂量免疫原性最佳,抗体反应非劣于RTS,S+AS01历史基准,支持推进人体CHMI试验。
要点
- FMP013+ALFQ在恒河猴中安全性良好,仅轻度局部反应,无血液或肝肾功能异常。
- 免疫后出现短暂全身炎症反应,包括白细胞升高、轻度发热,第7天恢复。
- 1 mL ALFQ+20 µg FMP013为最佳免疫原性剂量,抗体反应非劣于RTS,S+AS01。
核心结论
- FMP013联合ALFQ在恒河猴中安全耐受,诱导的抗体反应非劣于RTS,S+AS01历史基准,支持推进人体CHMI试验。
研究设计与样本
- 恒河猴研究:三组(每组n=6)分别接受半剂量或全人用剂量FMP013+ALFQ,按0-1-2月方案免疫。
- 兔GLP毒性研究:四剂方案评估ALFQ佐剂相关局部反应与全身炎症。
主要发现
- 恒河猴仅见轻度局部注射部位反应,无红细胞稳态、肝功能或肾功能异常。
- 免疫后出现短暂全身炎症反应,包括白细胞计数升高、轻度发热及少数肌酸激酶升高,第7天恢复至正常范围。
- 1 mL ALFQ+20 µg FMP013剂量免疫原性最佳;FMP013加倍至40 µg无影响,ALFQ减半至0.5 mL降低免疫原性。
- FMP013+ALFQ诱导的血清抗体可识别CSP分子所有区域,并诱导Th1偏向性细胞因子反应。
- 兔GLP毒性研究确认无局部部位反应,ALFQ佐剂给药相关短暂全身炎症。
关键数值与推荐
- 恒河猴最佳免疫原性剂量为1 mL ALFQ+20 µg FMP013。
- FMP013抗原加倍至40 µg对免疫原性无影响。
- ALFQ佐剂减半至0.5 mL降低免疫原性。
- 恒河猴抗体反应非劣于RTS,S+AS01在人体中的历史基准。
临床怎么用
- 该临床前数据支持FMP013+ALFQ推进至人体控制性疟疾感染(CHMI)试验。
- 恒河猴中1 mL ALFQ+20 µg FMP013为后续临床剂量选择提供参考。
- 免疫后短暂全身炎症反应可自行恢复,监测至第7天可确认恢复。
局限性
- 研究为动物实验(恒河猴和兔),尚未在人体中验证安全性与免疫原性。
- 样本量有限(每组n=6),统计效能受限。
- 长期保护效力与免疫记忆持续时间未在本次研究中评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antibodies to Circumsporozoite protein (CSP) confer protection against controlled human malaria infection (CHMI) caused by the parasite Plasmodium falciparum. Although CSP is highly immunogenic, it does not induce long lasting protection and efforts to improve CSP-specific immunological memory and duration of protection are underway. We have previously reported that the clinical grade CSP vaccine FMP013 was immunogenic and protective against malaria challenge in mice when combined with the Army Liposomal Formulation adjuvant containing immune modulators 3D-PHAD™ and QS21 (ALFQ). To move forward with clinical evaluation, we now report the safety, toxicity and immunogenicity of clinical grade FMP013 and ALFQ in Rhesus macaques. Three groups of Rhesus (n = 6) received half or full human dose of FMP013 + ALFQ on a 0-1-2 month schedule, which showed mild local site reactions with no hematologic derangements in red blood cell homeostasis, liver function or kidney function. Immunization induced a transient systemic inflammatory response, including elevated white blood cell counts, mild fever, and a few incidences of elevated creatine kinase, receding to normal range by day 7 post vaccination. Optimal immunogenicity in Rhesus was observed using a 1 mL ALFQ + 20 µg FMP013 dose. Doubling the FMP013 antigen dose to 40 µg had no effect while halving the ALFQ adjuvant dose to 0.5 mL lowered immunogenicity. Similar to data generated in mice, FMP013 + ALFQ induced serum antibodies that reacted to all regions of the CSP molecule and a Th1-biased cytokine response in Rhesus. Rhesus antibody response to FMP013 + ALFQ was found to be non-inferior to historical benchmarks including that of RTS,S + AS01 in humans. A four-dose GLP toxicity study in rabbits confirmed no local site reactions and transient systemic inflammation associated with ALFQ adjuvant administration. These safety and immunogenicity data support the clinical progression and testing of FMP013 + ALFQ in a CHMI trial in the near future.
引用
- Cawlfield A, Genito CJ, Beck Z, et al. Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ). Vaccine. 2019. PMID: 31151801. doi:10.1016/j.vaccine.2019.05.059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。